Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status

Poly (ADP-ribose) polymerase inhibitors (PARPi) have proven to be beneficial to patients with metastatic breast cancer with BRCA1/2 (BReast CAncer type 1 and type 2 genes) mutations. However, certain PARPi in pre-clinical studies have been shown to inhibit cell growth and promote the death of breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Keung, Man Yee, Wu, Yanyuan, Badar, Francesca, Vadgama, Jaydutt V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231148/
https://www.ncbi.nlm.nih.gov/pubmed/32235451
http://dx.doi.org/10.3390/jcm9040940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231148/
https://www.ncbi.nlm.nih.gov/pubmed/32235451
http://dx.doi.org/10.3390/jcm9040940

Ejemplares similares